Emmes, part of Emmes Group, a specialty tech-enabled global contract research organization (CRO), has been selected by the National Institutes of Health’s (NIH) NIDA (National Institute of Drug Abuse) to support their Clinical Trials Network (CTN) for a multi-task, IDIQ contract.
 
The management of NIDA Clinical Trial Network is supported by the Data and Statistical Coordinating Center (DSC) and the Clinical Coordinating Center (CCC), both done by Emmes. This new contract was awarded to Emmes ahead of two other bidders and sees that the CRO continues its long-standing partnership with the NIH – having held the previous DSC contracts since 2009 and CCC contracts since 2005.
 
The NIDA CTN is tasked with the goal of improving treatments and delivery for substance use disorder patients across the country. Emmes’ role as the CCC is to provide regulatory, safety, monitoring, training, and other clinical trial support and services as needed within the trials.
 
“We are incredibly proud to have been awarded this project by NIDA as the research they are undertaking is vital in advancing new understandings of drug addiction, potential treatments and improvements to care for patients with substance use disorders,” said Peter Ronco, CEO of Emmes.
 
The contract has a ceiling of $50 million and involves the award of three task orders as part of the IDIQ for the NIH’s National Institute on Drug Abuse Clinical Trials Network. These task orders include the NIH NIDA CTN HEAL Enhancement task, the NIH NIDA CTN Portfolio Support task, and the NIH NIDA CTN’s Clinical Coordinating Center Study task.